Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 2/20 | 0.62 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SLC6A1 | P30531 | 4/20 | 0.43 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.43 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1062937 | 1.00 | CPN1 (0.62) | CPN1CPB2KMT2ASLC6A1SLC6A11 | |
| SCHEMBL2268353 | 0.89 | SLC6A1 (0.53) | CPN1CPB2SLC6A1SLC6A11SLC6A13 | |
| SCHEMBL2268358 | 0.89 | SLC6A1 (0.53) | CPN1CPB2SLC6A1SLC6A11SLC6A13 | |
| SCHEMBL25661085 | 0.89 | SLC6A1 (0.53) | CPN1CPB2SLC6A1SLC6A11SLC6A13 | |
| SCHEMBL1798689 | 0.86 | CPN1 (0.54) | CPN1CPB2KMT2ASLC6A1SLC6A11 | |
| SCHEMBL1798686 | 0.86 | CPN1 (0.54) | CPN1CPB2KMT2ASLC6A1SLC6A11 | |
| SCHEMBL6371444 | 0.83 | CPN1 (0.51) | CPN1CPB2KMT2ASLC6A1SLC6A11 | |
| SCHEMBL2263033 | 0.81 | PTGS1 (0.39) | CPN1CPB2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL2263028 | 0.81 | PTGS1 (0.39) | CPN1CPB2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL24190465 | 0.81 | CPN1 (0.49) | CPN1CPB2KMT2ASLC6A1SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2722051-A1 | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus | Seattle Genetics, Inc. (US) | 2014-04-23 | — | — | EP | claimed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | claimed |
| EP-1917020-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2008-05-07 | — | — | EP | claimed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| EP-3498289-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20180355025-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS INC. | 2018-12-13 | — | — | US | disclosed |
| EP-2722051-B1 | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus | SEATTLE GENETICS INC (US) | 2018-11-07 | — | — | EP | disclosed |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | SEATTLE GENETICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-9828393-B2 | Silylalkyloxyaryl compounds and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160159832-A1 | SILYLALKYLOXYARYL COMPOUNDS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2016-06-09 | — | — | US | disclosed |
| EP-1917020-B1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS INC (US) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015013322-A1 | SILYLALKYLOXYARYL COMPOUNDS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-01-29 | — | — | WO | disclosed |
| EP-1917020-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-7071168-B2 | Anti-cancer compounds and methods related thereto | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2006-07-04 | — | — | US | disclosed |
| US-6388054-B1 | AMINO ACID SEQUENCES OF ANTITUMOR AGENTS AND APOPTOSIS AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-05-14 | — | — | US | disclosed |
| US-6197748-B1 | ANTICOAGULANTS | COR THERAPEUTICS, INC. | 2001-03-06 | — | — | US | disclosed |
| WO-2000011022-A1 | ANTI-CANCER COMPOUNDS AND METHODS RELATED THERETO | STEWART JOHN M (US) | 2000-03-02 | — | — | WO | disclosed |
| EP-0832102-A1 | KETOHETEROCYCLIC INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040744-A1 | KETOHETEROCYCLIC INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159832-A1 | SILYLALKYLOXYARYL COMPOUNDS AND METHODS FOR TREATING CANCER | BCL3, MYLK2, BCL2L13 | CPN1 3811/4885CPB2 3834/4885KMT2A 938/4885 |
| US-20180355025-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | CPN1 1976/4885CPB2 1766/4885KMT2A 1279/4885 |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | MMAB, DNPEP, MARCKS | CPN1 1904/4885CPB2 1657/4885KMT2A 1455/4885 |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | PTMS, MMAB, DNPEP | CPN1 1978/4885CPB2 1811/4885KMT2A 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.